Sensei Biotherapeutics, Inc. (SNSE): Price and Financial Metrics
SNSE Price/Volume Stats
| Current price | $0.93 | 52-week high | $1.72 |
| Prev. close | $0.97 | 52-week low | $0.51 |
| Day low | $0.91 | Volume | 65,800 |
| Day high | $1.05 | Avg. volume | 64,819 |
| 50-day MA | $0.95 | Dividend yield | N/A |
| 200-day MA | $0.88 | Market Cap | 23.34M |
SNSE Stock Price Chart Interactive Chart >
Sensei Biotherapeutics, Inc. (SNSE) Company Bio
Sensei Biotherapeutics, Inc. operates as a clinical-stage immunotherapy company. The Company focuses in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Sensei Biotherapeutics serves customers in the United States.
Latest SNSE News From Around the Web
Below are the latest news stories about SENSEI BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate SNSE as an investment opportunity.
Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial ResultsCompany's Cash Position Stands at $72.0 Million, R&D Expenses Decrease to $3.8 Million |
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported - - Phase 1/2 trial of SNS-101 continues to enroll ahead of schedule, with new clinical data milestones anticipated throughout 2024 - - Strong balance sheet with cash runway into the second half of 2025 - BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clini |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the trading week right with a breakdown of the biggest pre-market stock movers worth noting on Monday morning! |
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting- Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose cohorts - - First VISTA-blocking antibody administered at a dose anticipated to be therapeutically relevant without eliciting dose-limiting toxicity - - Monotherapy data from Phase 1/2 study to be presented in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual |
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business OfficerBOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer. Ms. Krebs joins Sensei from SNIPR Biome, a clinical-stage biotechnology company where, as Chief Business Officer, she was responsible for defining the company’s growth and partnering activit |
SNSE Price Returns
| 1-mo | -20.51% |
| 3-mo | 22.03% |
| 6-mo | 58.95% |
| 1-year | -41.14% |
| 3-year | -92.94% |
| 5-year | N/A |
| YTD | 34.39% |
| 2023 | -53.56% |
| 2022 | -74.31% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...